Cargando…

Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.

Forty-one adult patients with acute myelogenous leukaemia entered remission induced by daunorubicin and cytosine arabinoside, and subsequently received 6 weeks' consolidation therapy with cyclophosphamide plus 6-thioguanine. They were then randomized to either immunotherapy consisting of intrad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zuhrie, S. R., Harris, R., Freeman, C. B., MacIver, J. E., Geary, C. G., Delamore, I. W., Tooth, J. A.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1980
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010236/ https://www.ncbi.nlm.nih.gov/pubmed/6992827

Ejemplares similares

Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
por: Harris, R., et al.
Publicado: (1978)

Proceedings: Active immunotherapy in acute myeloid leukaemia.
por: Freeman, C. B., et al.
Publicado: (1975)

Immunotherapy for Acute Myelogenous Leukaemia
por: Powles, R. L., et al.
Publicado: (1973)

Granulocyte function in myeloblastic leukaemia.
por: Wilkinson, P. M., et al.
Publicado: (1975)

Myelogenic Leukaemia
Publicado: (1915)

Desacetylmethylcolchicine in the Treatment of Myeloid Leukaemia
por: Jelliffe, A. M., et al.
Publicado: (1956)

Myelogenous Leukæmia and Its Treatment
por: Debove,
Publicado: (1910)

Factors influencing prognosis in adults with acute myelogenous leukaemia.
por: Crowther, D., et al.
Publicado: (1975)

A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia
por: Hu, C. W., et al.
Publicado: (2019)

Further evidence of response by leukaemia patients in remission to antigen(s) related to acute myelogenous leukaemia.
por: Cocks, P., et al.
Publicado: (1977)

Cytogenetic analysis of leukaemic colonies from acute and chronic myelogenous leukaemia.
por: Trent, J. M., et al.
Publicado: (1983)

Acquired resistance to daunorubicin in a patient with acute myelogenous leukaemia.
por: Smith, B. J., et al.
Publicado: (1976)

Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.
por: Powles, R. L., et al.
Publicado: (1977)

In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.
por: Marie, J. P., et al.
Publicado: (1988)

Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia
por: Dalley, C D, et al.
Publicado: (2001)

Cell-mediated cytotoxicity as a result of immunotherapy in patients with acute myeloid leukaemia.
por: Taylor, G. M., et al.
Publicado: (1976)

Sensitivity of normal and acute myelogenous leukaemia marrow cells to inhibition by cytosine arabinoside.
por: Potter, C. G., et al.
Publicado: (1980)

Immunotherapy in leukaemia: Immunotherapy in leukaemia
por: Mu, Xingmei, et al.
Publicado: (2023)

Early central nervous system involvement in adults with acute non-myelogenous leukaemia.
por: Lister, T. A., et al.
Publicado: (1977)

Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia
por: Lee, C-Y, et al.
Publicado: (2007)

Proceedings: Cell mediated cytotoxicity (CMC) in patients with acute myeloblastic leukaemia receiving immunotherapy.
por: Taylor, G. M., et al.
Publicado: (1975)

Unclassifiable Leukaemias
por: Geary, C.
Publicado: (1976)

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
por: Cowan-Jacob, Sandra W., et al.
Publicado: (2006)

Familial platelet disorders with a predisposition to acute myelogenous leukaemia: a RUNX1 update
por: Rossini, J, et al.
Publicado: (2012)

The Acute Leukaemias
por: Geary, C. G.
Publicado: (1980)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Causación social
por: MacIver, R. M.
Publicado: (1942)

Partial characterization of a membrane antigen which exhibits specificity for cells of patients with acute myelogenous leukaemia.
por: Shipman, R., et al.
Publicado: (1983)

Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India
por: Anand, Maninder Singh, et al.
Publicado: (2012)

OGG1 rs1052133 Polymorphism and Genetic Susceptibility to Chronic Myelogenous Leukaemia
por: Hassan, Fathelrahman M
Publicado: (2019)

Misleading analyses
por: Harris, R., et al.
Publicado: (1978)

Growth inhibitory effects of interferon on blast cells from patients with acute myelogenous leukaemia.
por: Rohatiner, A. Z.
Publicado: (1984)

Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia
por: Ghosn, Youssef, et al.
Publicado: (2019)

Immunotherapy using BCG during remission induction and as the sole form of maintenance in acute myeloid leukaemia.
por: Summerfield, G. P., et al.
Publicado: (1979)

Generation of adherent lymphokine activated killer (A-LAK) cells from patients with acute myelogenous leukaemia.
por: Sedlmayr, P., et al.
Publicado: (1992)

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning
por: Topaly, J, et al.
Publicado: (2002)

Abused inhalants enhance GABA-mediated synaptic inhibition
por: MacIver, M. Bruce
Publicado: (2009)

Consciousness and inward electromagnetic field interactions
por: MacIver, M. Bruce
Publicado: (2022)

Synthesis and biological evaluation of dithiocarbamate esters of parthenolide as potential anti-acute myelogenous leukaemia agents
por: Ding, Yahui, et al.
Publicado: (2018)

The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cells
por: Naka, Kazuhito, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uttj2775na2ege4k1qa2u11s4i